Sutro Biopharma Receives the Pantheon 2015 DiNA Outstanding Partner Award by the California Life Sciences Association

Nov 18, 2015, 09:00 ET from Sutro Biopharma

SAN FRANCISCO, Nov. 18, 2015 /PRNewswire/ -- Sutro Biopharma today announced that it was awarded the Outstanding Partner Award, at the California Life Sciences Association (CLSA) annual Pantheon Ceremony 2015 Presenting DiNA Awards.  Late last year, Sutro entered into a broad strategic collaboration and option agreement with Celgene Corporation to discover and develop multi-specific antibodies and antibody drug conjugates (ADCs) in the field of immuno-oncology.  In addition, Sutro entered a multi-target strategic collaboration with EMD Serono (Merck KGaA) to discover and develop antibody drug conjugates (ADCs).  Sutro's cell-free biologics development platforms, Xpress CF and Xpress CF+ are key elements to its strategic collaborations, driving forward the development of next generation immuno-oncology therapeutics. The CLSA has recognized Northern California based Sutro, for its life science achievements throughout the year.

William Newell, chief executive officer of Sutro Biopharma, said, "We are honored to pioneer a new generation of cancer therapeutics with our partners Celgene and EMD Serono. This award recognizes our partnerships as first-rate collaborations designed to achieve the best for patients and health care providers. Our platform and product development efforts bear enormous promise.  These collaborations have worked to accelerate the development of oncology therapeutics, with compelling patient benefit."

About Sutro Biopharma

Sutro Biopharma, Inc., located in South San Francisco, develops best-in-class antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy, including Immuno-Oncology therapies. Sutro's discovery and development efforts are driven by our proprietary Xpress CF™ and Xpress CF+™ platforms, a biochemical synthesis system that enables rapid and systematic evaluation of protein structure-activity relationships, as well as rapid and predictable scalability for manufacturing in Sutro's cGMP facility. In addition to developing its own drug candidate pipeline, which is focused on mono- and bi-specific ADCs, Sutro Biopharma is collaborating with select pharmaceutical and biotech companies to discover and develop novel therapeutics.

Media Contacts:

David Schull or Christopher Hippolyte
Russo Partners
(212) 845-4271
(646)942-5634
david.schull@russopartnersllc.com 
chris.hippolyte@russopartnersllc.com

SOURCE Sutro Biopharma